NCT05766787

Brief Summary

The purpose of this study is to assess the clinical performance of two reusable silicone hydrogel contact lenses when worn on a daily wear basis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
190

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

15 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 1, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 13, 2023

Completed
16 days until next milestone

Study Start

First participant enrolled

March 29, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 2, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 2, 2023

Completed
1 year until next milestone

Results Posted

Study results publicly available

June 13, 2024

Completed
Last Updated

June 13, 2024

Status Verified

May 1, 2024

Enrollment Period

2 months

First QC Date

March 1, 2023

Results QC Date

May 17, 2024

Last Update Submit

May 17, 2024

Conditions

Keywords

Myopia

Outcome Measures

Primary Outcomes (1)

  • Least Squares Mean Distance VA With Study Lenses at Week 1

    Visual acuity (VA) was assessed for each eye individually with study lenses in place using logarithmic of the Minimum Angle of Resolution (logMAR) reading charts. LogMAR values typically range from -0.3 (20/10 vision on the Snellen chart) to 1 (20/200 vision). A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal distance visual acuity), with a negative value denoting better than 20/20 visual acuity.

    Week 1 of each lens product worn during the corresponding crossover period

Study Arms (2)

LID022821, then AOHP

OTHER

Serafilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection.

Device: Serafilcon A contact lensesDevice: Senofilcon A contact lensesDevice: CLEAR CARE

AOHP, then LID022821

OTHER

Senofilcon A contact lenses worn first, with serafilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection.

Device: Serafilcon A contact lensesDevice: Senofilcon A contact lensesDevice: CLEAR CARE

Interventions

Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection

Also known as: LID022821
AOHP, then LID022821LID022821, then AOHP

Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection

Also known as: ACUVUE OASYS® with HYDRACLEAR® PLUS Technology, AOHP
AOHP, then LID022821LID022821, then AOHP

Hydrogen peroxide based contact lens cleaning and disinfecting solution

Also known as: CLEAR CARE® Cleaning and Disinfecting Solution
AOHP, then LID022821LID022821, then AOHP

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Successful wear of spherical soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months.
  • Best Corrected Visual Acuity (BCVA) of 20/25 Snellen (0.10 logMAR) or better in each eye.
  • Willing to stop wearing habitual contact lenses for the duration of study participation.

You may not qualify if:

  • Any eye infection, inflammation, abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the investigator.
  • Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator.
  • Habitual wear of AOHP contact lenses.
  • Habitual wear of any daily disposable contact lenses.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

Kurata Eyecare Center

Los Angeles, California, 90013, United States

Location

Dr. Elsa Pao, OD

Oakland, California, 94607, United States

Location

Pacific Rims Optometry

San Francisco, California, 94127, United States

Location

Omega Vision Center P.A.

Longwood, Florida, 32779, United States

Location

Kindred Optics at Maitland Vision

Maitland, Florida, 32751, United States

Location

Vision Health Institute

Orlando, Florida, 32803, United States

Location

Tallahassee Eye Center

Tallahassee, Florida, 32308, United States

Location

Heart of America Eye Care

Shawnee Mission, Kansas, 66204, United States

Location

The Eye Doctors Inc

Eden Prairie, Minnesota, 55344, United States

Location

Complete Eye Care of Medina

Medina, Minnesota, 55340, United States

Location

SUNY College of Optometry Clinical Vision Research Center

New York, New York, 10036, United States

Location

ProCare Vision Centers, Inc.

Granville, Ohio, 43023, United States

Location

West Bay Eye Associates

Warwick, Rhode Island, 02888, United States

Location

Optometry Group, PLLC

Memphis, Tennessee, 38111, United States

Location

Total Eye Care PA

Memphis, Tennessee, 38119, United States

Location

MeSH Terms

Conditions

Myopia

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Results Point of Contact

Title
Clinical Project Lead, Vision Care
Organization
Alcon Research, LLC

Study Officials

  • Clinical Trial Lead Alcon Vision Care

    Alcon Research, LLC

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 1, 2023

First Posted

March 13, 2023

Study Start

March 29, 2023

Primary Completion

June 2, 2023

Study Completion

June 2, 2023

Last Updated

June 13, 2024

Results First Posted

June 13, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations